Biotech · Private company · Cambridge, MA, US
Syros Pharmaceuticals, Inc.
SEC CIK 0001556263
Track this companyFree. Adds Syros Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- AzacitidinePhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- TamibarotenePhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- DaratumumabPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- TamibarotenePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Arsenic TrioxidePhase 1 · Acute Promyelocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxelPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- SY-1365 (Cohort 2)Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SY-1365 (Cohort 5)Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SY-1365 (Part 1)Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SY-1365 (Part 2 Single Agent)Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SY-2101Phase 1 · Acute Promyelocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- SY-5609Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Study for Oral SY-2101 for Participants With Acute Promyelocytic LeukemiaPHASE1 · SUSPENDED · started Sep 17, 2021ClinicalTrials.gov NCT04996030 · fetched Nov 12, 2026
- Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)PHASE2 · TERMINATED · started Aug 26, 2021ClinicalTrials.gov NCT04905407 · fetched Nov 12, 2026
- Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic SyndromePHASE3 · TERMINATED · started Feb 8, 2021ClinicalTrials.gov NCT04797780 · fetched Nov 12, 2026
- A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid TumorsPHASE1 · COMPLETED · started Jan 23, 2020ClinicalTrials.gov NCT04247126 · fetched Nov 12, 2026
- A Study of SY-1365 in Adult Patients With Advanced Solid TumorsPHASE1 · TERMINATED · started May 12, 2017ClinicalTrials.gov NCT03134638 · fetched Nov 12, 2026
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic SyndromePHASE2 · COMPLETED · started Sep 20, 2016ClinicalTrials.gov NCT02807558 · fetched Nov 12, 2026
SEC filings6
- 8-K · 8-KSEC EDGAR · filed Mar 4, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 28, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 8, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 6, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 18, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 13, 2024 · fetched Nov 12, 2026